Lakefront Biotherapeutics (LKFT) Research & Development (2016 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Research & Development of -$36.2 million for Q1 2026, up 81.14% year-over-year from -$20.0 million in Q1 2025, and down 103.84% quarter-over-quarter from $944.4 million in Q4 2025.
Lakefront Biotherapeutics (LKFT) Research & Development (2016 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Research & Development for 11 consecutive years, with -$36.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 81.14% year-over-year to -$36.2 million; the TTM figure through Mar 2026 stood at $704.1 million (up 197.67% YoY), while the FY2025 annual figure was $534.8 million, up 49.19% from the prior year.
- Research & Development retreated to -$36.2 million in Q1 2026 per LKFT's latest filing, from $944.4 million in the prior quarter.
- Across five years, Research & Development topped out at $944.4 million in Q4 2025 and bottomed at -$396.8 million in Q3 2025.
- Historically, Research & Development has averaged $122.8 million across 5 years, with a median of -$32.5 million in 2022.
- On a YoY basis, Research & Development climbed as much as 196.58% in 2025 and fell as far as 147.09% in 2025.
- Lakefront Biotherapeutics' Research & Development stood at $382.7 million in 2022, then rose by 14.85% to $439.5 million in 2023, then jumped by 39.49% to $613.1 million in 2024, then soared by 54.04% to $944.4 million in 2025, then plunged by 103.84% to -$36.2 million in 2026.
- Business Quant data shows LKFT's Research & Development at -$36.2 million in Q1 2026, $944.4 million in Q4 2025, and -$396.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Lakefront Biotherapeutics | 1.81 Bn | -1.68 Bn | 1.97 Mn | -36.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.25 Mn |
| Dec 31, 2025 | 944.42 Mn |
| Sep 30, 2025 | -396.77 Mn |
| Jun 30, 2025 | 192.70 Mn |
| Mar 31, 2025 | -192.23 Mn |
| Dec 31, 2024 | 613.08 Mn |
| Sep 30, 2024 | -249.29 Mn |
| Jun 30, 2024 | 64.97 Mn |
| Mar 31, 2024 | -77.80 Mn |
| Dec 31, 2023 | 439.53 Mn |
| Mar 31, 2023 | -56.41 Mn |
| Dec 31, 2022 | 382.70 Mn |
| Mar 31, 2022 | -32.53 Mn |
| Jun 30, 2021 | -17.48 Mn |
| Mar 31, 2021 | -17.53 Mn |
| Jun 30, 2020 | -18.82 Mn |
| Mar 31, 2020 | -10.86 Mn |
| Dec 31, 2019 | 475.73 Mn |
| Sep 30, 2019 | -4.54 Mn |
| Jun 30, 2019 | -4.35 Mn |